Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that two phase III trials demonstrated the effectiveness of the oral Janus kinase inhibitor baricitinib at 2 mg or 4 mg daily for treating severe alopecia areata in adults, marking a potential advance in managing this condition.

In this case report, a 55-year-old woman developed alopecia areata approximately one year into her treatment with upadacitinib for atopic dermatitis, raising questions about a potential drug-induced link that has not been reported before.

In this report, oral baricitinib improved both alopecia areata and immune thrombocytopenia in a 56-year-old patient, suggesting a potential dual benefit for these conditions, although regular platelet monitoring and hematology consultation are recommended.

This systematic review evaluated the safety of JAK-inhibitors for alopecia areata, finding that most adverse events were mild and systemic formulations were well-tolerated; however, increased rates of certain infections and laboratory abnormalities were noted, with isolated severe cases but no fatal outcomes.

In this prospective study, ritlecitinib effectively reduced hair loss in patients with severe alopecia areata, with 43.3% of participants achieving a 20 or lower SALT score by week 24, and showed a good midterm safety profile.

This study examined phase 3 clinical trial data and found that baricitinib improves hair regrowth in adults with alopecia areata and significant scalp hair loss, with the response varying based on the severity of hair loss at the start of treatment.

This announcement discusses the recent FDA approval of baricitinib for treating severe alopecia areata in adults and reports no new clinical results.

This study identified new and recurrent missense mutations in the PHGDH and PSAT1 genes, implicating them in the pathogenesis of Neu-Laxova syndrome in Chinese patients.

This study evaluated the real-world use of ritlecitinib for severe alopecia areata in the UK, reporting that 37% of patients achieved significant hair regrowth by week 36, with no serious adverse effects noted, although response varied with disease duration.

In this study, patients with severe alopecia areata treated with baricitinib over 152 weeks experienced sustained patient-reported improvements in scalp, eyebrow, and eyelash hair regrowth, with higher responders observed in the 4mg dose group compared to the 2mg group.

In this study, data from multiple sources found that Baricitinib significantly promoted hair regrowth and improved patient-reported outcomes in those with severe alopecia, with minimal side effects, over a 36-week period.

Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.

In these randomized, placebo-controlled trials, patients with alopecia areata who received baricitinib showed significantly higher eyebrow and eyelash hair regrowth rates compared to placebo, with greater responses observed at the 4 mg dose and in those achieving overall scalp hair improvement by Week 52.

ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.

This case report highlights that Baricitinib led to significant hair regrowth and resolution of atopic dermatitis symptoms in a 22-year-old female with coexisting autoimmune conditions.

Ivarmacitinib effectively regrows hair in severe alopecia areata.

This study found that albumin-bound paclitaxel combined with nedaplatin shows promise as neoadjuvant therapy for esophageal squamous cell carcinoma, achieving a high complete response rate with manageable side effects.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

This case report describes successful treatment of alopecia areata and atopic dermatitis in a pediatric patient using the Janus kinase 1 inhibitor upadacitinib, with significant hair growth improvements noted after six weeks.

This case study reported that a 24-year-old patient with severe, treatment-resistant alopecia areata experienced excellent clinical improvement after one month of treatment with tofacitinib, a JAK inhibitor.

This review examined the common side effects of FGFR inhibitors like erdafitinib, pemigatinib, and futibatinib, and detailed strategies for managing them, highlighting that proactive monitoring and appropriate interventions can effectively mitigate these toxicities.

In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.

This study described a case where both alopecia universalis and Crohn's ileitis in a 23-year-old man showed remarkable improvement with the JAK1 inhibitor upadacitinib, highlighting its potential as a treatment for patients with concurrent conditions.

In this report, NICE has approved ritlecitinib, an oral kinase inhibitor, as the first recommended treatment for severe alopecia areata in individuals aged 12 and older.

In this study, baricitinib treatment for severe alopecia areata was associated with complete hair regrowth after 12 months in two patients, suggesting it may be an effective alternative to traditional therapies, although safety and clinical implications need careful consideration.

This study found that a single ablative fractional laser treatment significantly reduced hedgehog pathway gene expression in microscopic murine basal cell carcinomas, nearly matching the effects of repeated topical vismodegib applications.

The study found that IPI-926 was well tolerated up to 160 mg once daily for 28-day cycles and showed activity as a single-agent treatment in Hedgehog pathway inhibitor-naïve patients with basal cell carcinoma.

Erlotinib can cause hair loss and scalp issues, which improve after stopping the drug.